Clinical Trial Update: Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing T1225 1.5% to Tobramycin 0.3% for purulent bacterial conjunctivitis has completed, evaluating efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Conjunctivitis

Drugs mentioned

• T1225 1.5%
• Tobramycin 0.3% (tobramycin)

Snippet

Sponsor: Laboratoires Thea | Conditions: Conjunctivitis, Bacterial | Phase 3 | Status: COMPLETED